{"protocolSection": {"identificationModule": {"nctId": "NCT01870739", "orgStudyIdInfo": {"id": "CLCZ696A2224"}, "secondaryIdInfos": [{"id": "2012-005720-15", "type": "EUDRACT_NUMBER"}], "organization": {"fullName": "Novartis", "class": "INDUSTRY"}, "briefTitle": "A Study to Evaluate the Effect of LCZ696 on Aortic Stiffness in Subjects With Hypertension", "officialTitle": "A Randomized, Double-blind, Active-controlled, Parallel Group, 52-week Study to Evaluate the Effect of LCZ696 Compared to Olmesartan on Regional Aortic Stiffness in Subjects With Essential Hypertension"}, "statusModule": {"statusVerifiedDate": "2019-03", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2013-10"}, "primaryCompletionDateStruct": {"date": "2015-06", "type": "ACTUAL"}, "completionDateStruct": {"date": "2015-06", "type": "ACTUAL"}, "studyFirstSubmitDate": "2013-06-03", "studyFirstSubmitQcDate": "2013-06-03", "studyFirstPostDateStruct": {"date": "2013-06-06", "type": "ESTIMATED"}, "resultsFirstSubmitDate": "2016-05-31", "resultsFirstSubmitQcDate": "2016-07-20", "resultsFirstPostDateStruct": {"date": "2016-09-01", "type": "ESTIMATED"}, "lastUpdateSubmitDate": "2020-12-09", "lastUpdatePostDateStruct": {"date": "2021-01-05", "type": "ACTUAL"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "Novartis Pharmaceuticals", "class": "INDUSTRY"}}, "oversightModule": {"oversightHasDmc": false}, "descriptionModule": {"briefSummary": "This was the first evaluation of the effects of LCZ696 on local and regional measures of aortic stiffness in subjects with mild to moderate hypertension and widened pulse pressure. The results of this exploratory study will help to understand the mechanism of action of LCZ696 and used to inform the design of future clinical studies with LCZ696 in subjects with cardiovascular diseases."}, "conditionsModule": {"conditions": ["Hypertension"], "keywords": ["LCZ696,", "Hypertension,", "Aortic stiffness,", "Central blood pressure,", "Cardiovascular MRI"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE2"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "PARALLEL", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "QUADRUPLE", "whoMasked": ["PARTICIPANT", "CARE_PROVIDER", "INVESTIGATOR", "OUTCOMES_ASSESSOR"]}}, "enrollmentInfo": {"count": 115, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "sacubitril/valsartan (LCZ696)", "type": "EXPERIMENTAL", "description": "Single drug treatment period: Patients received LCZ696 200mg once daily (q.d.) + placebo to 20 mg olmesartan q.d for 2 weeks. After 2 weeks, patients were dosed at the maintenance dose level (400 mg qd LCZ696 + placebo to 40 mg qd olmesartan) for 10 weeks.\n\nAdd-on Period: After 12 weeks on single-drug treatment, patients continued in the study on the blinded maintenance dose and if required, open label amlodipine (2.5 mg, 5 mg, or 10 mg qd) was added to the treatment regimen and titrated according to the investigator's discretion to achieve target blood pressure.", "interventionNames": ["Drug: sacubitril/valsartan (LCZ696)", "Other: placebo to olmesartan", "Drug: Amlodipine (Optional)"]}, {"label": "olmesartan", "type": "ACTIVE_COMPARATOR", "description": "Single drug treatment period: Patients received 20 mg olmesartan q.d + placebo to LCZ696 200mg once daily (q.d.) for 2 weeks. After 2 weeks, patients were dosed at the maintenance dose level (40 mg olmesartan q.d + placebo to 400 mg qd LCZ696) for 10 weeks.\n\nAdd-on Period: After 12 weeks on single-drug treatment, patients continued in the study on the blinded maintenance dose and if required, open label amlodipine (2.5 mg, 5 mg, or 10 mg qd) was added to the treatment regimen and titrated according to the investigator's discretion to achieve target blood pressure.", "interventionNames": ["Drug: olmesartan", "Other: placebo to sacubitril/valsartan (LCZ696)", "Drug: Amlodipine (Optional)"]}], "interventions": [{"type": "DRUG", "name": "sacubitril/valsartan (LCZ696)", "description": "200 mg tablets", "armGroupLabels": ["sacubitril/valsartan (LCZ696)"]}, {"type": "DRUG", "name": "olmesartan", "armGroupLabels": ["olmesartan"]}, {"type": "OTHER", "name": "placebo to sacubitril/valsartan (LCZ696)", "description": "placebo", "armGroupLabels": ["olmesartan"]}, {"type": "OTHER", "name": "placebo to olmesartan", "description": "placebo", "armGroupLabels": ["sacubitril/valsartan (LCZ696)"]}, {"type": "DRUG", "name": "Amlodipine (Optional)", "description": "If required, open label amlodipine (2.5 mg, 5 mg, or 10 mg qd) was added to treatment regimen", "armGroupLabels": ["olmesartan", "sacubitril/valsartan (LCZ696)"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Change From Baseline in Ascending Aorta Distensibility at 52 Week", "description": "Cardiovascular magnetic resonance imaging (MRI) scans were obtained at baseline prior to randomization, at week 52 for the assessment of local aortic distensibility. Ascending aorta distensibility was one of the 3 components for measuring local arota distensibility.", "timeFrame": "Baseline, 52 weeks"}, {"measure": "Change From Baseline in Proximal Descending Aorta Distensibility at 52 Weeks", "description": "Cardiovascular magnetic resonance imaging (MRI) scans were obtained at baseline prior to randomization, at week 52 for the assessment of local aortic distensibility. Proximal descending aorta distensibility was one of the 3 components for measuring local arota distensibility.", "timeFrame": "Baseline, 52 weeks"}, {"measure": "Change From Baseline in Distal Descending Aorta Distensibility at 52 Weeks", "description": "Cardiovascular magnetic resonance imaging (MRI) scans were obtained at baseline prior to randomization, at week 52 for the assessment of local aortic distensibility. Distal descending aorta distensibility was one of the 3 components for measuring local arota distensibility.", "timeFrame": "Baseline, 52 weeks"}], "secondaryOutcomes": [{"measure": "Change From Baseline in Local Aortic Strain at 52 Weeks", "description": "Cardiovascular magnetic resonance imaging (MRI) scans were obtained at baseline prior to randomization, at week 52 for the assessment of local aortic strain. Local aortic strain was measured by assessing ascending aorta strain, proximal descending aorta strain and distal descending aorta strain.", "timeFrame": "Baseline, 52 weeks"}, {"measure": "Change From Baseline in Regional Aortic Pulse Wave Velocity at 52 Weeks", "description": "Cardiovascular magnetic resonance imaging (MRI) scans were obtained at baseline prior to randomization, at week 52 for the assessment of regional aortic pulse wave velocity.", "timeFrame": "Baseline, 52 weeks"}, {"measure": "Change From Baseline in Central Blood Pressure at 52 Weeks", "description": "Central blood pressure was determined by measuring central systolic blood pressure , diastolic blood pressure and pulse pressure.", "timeFrame": "Baseline, 52 weeks"}, {"measure": "Change From Baseline in Augmentation Pressure at 52 Weeks", "description": "Augmentation pressure is the added pressure during systole due to wave reflection.", "timeFrame": "Baseline, 52 weeks"}, {"measure": "Change From Baseline in Augmentation Index at 52 Weeks", "description": "Augmentation index (Alx) is the percentage of the central pulse pressure due to wave reflection.", "timeFrame": "Baseline, 52 weeks"}, {"measure": "Change From Baseline in Carotid-femoral Pulse Wave Velocity at 52 Weeks", "description": "For pulse wave velocity calculation, the pressure waveform at the femoral site (using a partially inflated custom blood pressure cuff) and the carotid site (using hand -held applanation tonometry) were measured simultaneously. Pulse wave analysis was performed on the central aortic pressure waveform as derived from the brachial pressure waveform recorded in a partially-inflated blood pressure cuff around the upper arm.", "timeFrame": "Baseline, 52 weeks"}, {"measure": "Number of Patients With Reported Adverse Events, Serious Adverse Events and Death", "description": "This outcome measure summarizes patients with any adverse events, serious adverse events and death.", "timeFrame": "12 weeks"}]}, "eligibilityModule": {"eligibilityCriteria": "Key Inclusion Criteria:\n\n* Subjects with essential hypertension, untreated or currently taking antihypertensive therapy\n\nKey exclusion Criteria:\n\n* women of child bearing potential (WOCBP) if not on highly effective contraception\n* Malignant or severe hypertension (grade 3 of WHO classification)\n* History or evidence of a secondary form of hypertension\n* Transient ischemic cerebral attack (TIA) during the 12 months prior to screening or any history of stroke.\n* Previous or current diagnosis of heart failure (New York Heart Association Class II-IV).", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "18 Years", "stdAges": ["ADULT", "OLDER_ADULT"]}, "contactsLocationsModule": {"overallOfficials": [{"name": "Novartis Pharmaceuticals", "affiliation": "Novartis Pharmaceuticals", "role": "STUDY_DIRECTOR"}], "locations": [{"facility": "Novartis Investigative Site", "city": "Berlin", "zip": "10117", "country": "Germany", "geoPoint": {"lat": 52.52437, "lon": 13.41053}}, {"facility": "Novartis Investigative Site", "city": "Erlangen", "zip": "91054", "country": "Germany", "geoPoint": {"lat": 49.59099, "lon": 11.00783}}, {"facility": "Novartis Investigative Site", "city": "Basel", "zip": "4031", "country": "Switzerland", "geoPoint": {"lat": 47.55839, "lon": 7.57327}}, {"facility": "Novartis Investigative Site", "city": "Glasgow", "state": "Scotland", "zip": "G12 8TA", "country": "United Kingdom", "geoPoint": {"lat": 55.86515, "lon": -4.25763}}]}, "referencesModule": {"references": [{"pmid": "33778551", "type": "DERIVED", "citation": "Hrabak-Paar M, Kircher A, Al Sayari S, Kopp S, Santini F, Schmieder RE, Kachenoura N, Yates D, Langenickel T, Bremerich J, Heye T. Variability of MRI Aortic Stiffness Measurements in a Multicenter Clinical Trial Setting: Intraobserver, Interobserver, and Intracenter Variability of Pulse Wave Velocity and Aortic Strain Measurement. Radiol Cardiothorac Imaging. 2020 Apr 30;2(2):e190090. doi: 10.1148/ryct.2020190090. eCollection 2020 Apr."}, {"pmid": "33012283", "type": "DERIVED", "citation": "Santini F, Pansini M, Hrabak-Paar M, Yates D, Langenickel TH, Bremerich J, Bieri O, Schubert T. On the optimal temporal resolution for phase contrast cardiovascular magnetic resonance imaging: establishment of baseline values. J Cardiovasc Magn Reson. 2020 Oct 5;22(1):72. doi: 10.1186/s12968-020-00669-1."}], "seeAlsoLinks": [{"label": "A Plain Language Trial Summary is available on novartisclinicaltrials.com", "url": "https://www.novctrd.com/ctrdweb/patientsummary/patientsummaries?patientSummaryId=32"}]}}, "resultsSection": {"participantFlowModule": {"recruitmentDetails": "A total of 115 patients were enrolled. One patient was discontinued after randomization before receiving any dose of study randomized medication.\n\nA total of 114 patients received study randomized medication", "groups": [{"id": "FG000", "title": "Sacubitril/Valsartan (LCZ696)", "description": "LCZ696 based treatment strategy (LCZ696 200 mg for 2 weeks as initiation dose, LCZ696 400 mg for additional 50 weeks as maintenance dose. Optional amlodipine 2.5 to 10 mg add-on after Week 12 to reach blood pressure target)"}, {"id": "FG001", "title": "Olmesartan", "description": "Olmesartan based treatment strategy (olmesartan 20 mg for 2 weeks as initiation dose, olmesartan 40 mg for additional 50 weeks as maintenance dose. Optional amlodipine 2.5 to 10 mg add-on after Week 12 to reach blood pressure target)"}], "periods": [{"title": "Single Drug Treatment (12 Weeks)", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "comment": "\"Start\" = Safety/Pharmacokinetic/Pharmacodynamic analysis set", "numSubjects": "57"}, {"groupId": "FG001", "numSubjects": "57"}]}, {"type": "Initiation Dose Completed", "achievements": [{"groupId": "FG000", "numSubjects": "57"}, {"groupId": "FG001", "numSubjects": "56"}]}, {"type": "Maintenance Dose Started", "achievements": [{"groupId": "FG000", "numSubjects": "57"}, {"groupId": "FG001", "numSubjects": "56"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "comment": "\"Completed\" indicates maintenance dose complete", "numSubjects": "54"}, {"groupId": "FG001", "numSubjects": "53"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "3"}, {"groupId": "FG001", "numSubjects": "4"}]}], "dropWithdraws": [{"type": "Protocol deviation", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "1"}]}, {"type": "Adverse Event", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "1"}]}, {"type": "Administrative problems", "reasons": [{"groupId": "FG000", "numSubjects": "3"}, {"groupId": "FG001", "numSubjects": "2"}]}]}, {"title": "Add-on Period (40 Weeks)", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "54"}, {"groupId": "FG001", "numSubjects": "53"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "51"}, {"groupId": "FG001", "numSubjects": "51"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "3"}, {"groupId": "FG001", "numSubjects": "2"}]}], "dropWithdraws": [{"type": "Adverse Event", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "1"}]}, {"type": "Unsatisfactory therapeutic effect", "reasons": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "0"}]}, {"type": "Protocol deviation", "reasons": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "1"}]}, {"type": "Patient withdrew consent", "reasons": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "0"}]}]}]}, "baselineCharacteristicsModule": {"populationDescription": "Safety analysis set: All patients that received study drug", "groups": [{"id": "BG000", "title": "Sacubitril/Valsartan (LCZ696)", "description": "LCZ696 based treatment strategy (LCZ696 200 mg for 2 weeks as initiation dose, LCZ696 400 mg for additional 50 weeks as maintenance dose. Optional amlodipine 2.5 to 10 mg add-on after Week 12 to reach blood pressure target)"}, {"id": "BG001", "title": "Olmesartan", "description": "Olmesartan based treatment strategy (olmesartan 20 mg for 2 weeks as initiation dose, olmesartan 40 mg for additional 50 weeks as maintenance dose. Optional amlodipine 2.5 to 10 mg add-on after Week 12 to reach blood pressure target)"}, {"id": "BG002", "title": "Total", "description": "Total of all reporting groups"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "57"}, {"groupId": "BG001", "value": "57"}, {"groupId": "BG002", "value": "114"}]}], "measures": [{"title": "Age, Continuous", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "Years", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "60.5", "spread": "7.8"}, {"groupId": "BG001", "value": "59.2", "spread": "13.1"}, {"groupId": "BG002", "value": "59.8", "spread": "10.7"}]}]}]}, {"title": "Sex: Female, Male", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "20"}, {"groupId": "BG001", "value": "17"}, {"groupId": "BG002", "value": "37"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "37"}, {"groupId": "BG001", "value": "40"}, {"groupId": "BG002", "value": "77"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "Change From Baseline in Ascending Aorta Distensibility at 52 Week", "description": "Cardiovascular magnetic resonance imaging (MRI) scans were obtained at baseline prior to randomization, at week 52 for the assessment of local aortic distensibility. Ascending aorta distensibility was one of the 3 components for measuring local arota distensibility.", "populationDescription": "Pharmacodynamic (PD) analysis set: All patients with any available PD data, who received any study drug and experienced no protocol deviations with relevant impact on PD data. Patients with both baseline and week 52 data were included in this analysis.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "10^(-3) x mmHg^(-1)", "timeFrame": "Baseline, 52 weeks", "groups": [{"id": "OG000", "title": "Sacubitril/Valsartan (LCZ696)", "description": "LCZ696 based treatment strategy (LCZ696 200 mg for 2 weeks as initiation dose, LCZ696 400 mg for additional 50 weeks as maintenance dose. Optional amlodipine 2.5 to 10 mg add-on after Week 12 to reach blood pressure target)"}, {"id": "OG001", "title": "Olmesartan", "description": "Olmesartan based treatment strategy (olmesartan 20 mg for 2 weeks as initiation dose, olmesartan 40 mg for additional 50 weeks as maintenance dose. Optional amlodipine 2.5 to 10 mg add-on after Week 12 to reach blood pressure target)"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "49"}, {"groupId": "OG001", "value": "53"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0.269", "spread": "0.1283"}, {"groupId": "OG001", "value": "0.330", "spread": "0.1233"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "nonInferiorityType": "SUPERIORITY_OR_OTHER_LEGACY", "pValue": "0.7324", "statisticalMethod": "Linear Model", "statisticalComment": "Treatment as fixed effect and corresponding baseline as covariate.", "paramType": "Mean Difference (Net)", "paramValue": "-0.0616", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.4178", "ciUpperLimit": "0.2947"}]}, {"type": "PRIMARY", "title": "Change From Baseline in Proximal Descending Aorta Distensibility at 52 Weeks", "description": "Cardiovascular magnetic resonance imaging (MRI) scans were obtained at baseline prior to randomization, at week 52 for the assessment of local aortic distensibility. Proximal descending aorta distensibility was one of the 3 components for measuring local arota distensibility.", "populationDescription": "Pharmacodynamic (PD) analysis set: All patients with any available PD data, who received any study drug and experienced no protocol deviations with relevant impact on PD data. Patients with both baseline and week 52 data were included in this analysis.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "10^(-3) x mmHg^(-1)", "timeFrame": "Baseline, 52 weeks", "groups": [{"id": "OG000", "title": "Sacubitril/Valsartan (LCZ696)", "description": "LCZ696 based treatment strategy (LCZ696 200 mg for 2 weeks as initiation dose, LCZ696 400 mg for additional 50 weeks as maintenance dose. Optional amlodipine 2.5 to 10 mg add-on after Week 12 to reach blood pressure target)"}, {"id": "OG001", "title": "Olmesartan", "description": "Olmesartan based treatment strategy (olmesartan 20 mg for 2 weeks as initiation dose, olmesartan 40 mg for additional 50 weeks as maintenance dose. Optional amlodipine 2.5 to 10 mg add-on after Week 12 to reach blood pressure target)"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "49"}, {"groupId": "OG001", "value": "53"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0.510", "spread": "0.1528"}, {"groupId": "OG001", "value": "0.547", "spread": "0.1469"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "nonInferiorityType": "SUPERIORITY_OR_OTHER_LEGACY", "pValue": "0.8614", "statisticalMethod": "Linear Model", "statisticalComment": "Treatment as a fixed effect and corresponding baseline as a covariate", "paramType": "Mean Difference (Net)", "paramValue": "-0.0371", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.4582", "ciUpperLimit": "0.3839"}]}, {"type": "PRIMARY", "title": "Change From Baseline in Distal Descending Aorta Distensibility at 52 Weeks", "description": "Cardiovascular magnetic resonance imaging (MRI) scans were obtained at baseline prior to randomization, at week 52 for the assessment of local aortic distensibility. Distal descending aorta distensibility was one of the 3 components for measuring local arota distensibility.", "populationDescription": "Pharmacodynamic (PD) analysis set: All patients with any available PD data, who received any study drug and experienced no protocol deviations with relevant impact on PD data. Patients with both baseline and week 52 data were included in this analysis.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "10^(-3) x mmHg^(-1)", "timeFrame": "Baseline, 52 weeks", "groups": [{"id": "OG000", "title": "Sacubitril/Valsartan (LCZ696)", "description": "LCZ696 based treatment strategy (LCZ696 200 mg for 2 weeks as initiation dose, LCZ696 400 mg for additional 50 weeks as maintenance dose. Optional amlodipine 2.5 to 10 mg add-on after Week 12 to reach blood pressure target)"}, {"id": "OG001", "title": "Olmesartan", "description": "Olmesartan based treatment strategy (olmesartan 20 mg for 2 weeks as initiation dose, olmesartan 40 mg for additional 50 weeks as maintenance dose. Optional amlodipine 2.5 to 10 mg add-on after Week 12 to reach blood pressure target)"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "49"}, {"groupId": "OG001", "value": "53"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0.417", "spread": "0.2242"}, {"groupId": "OG001", "value": "0.498", "spread": "0.2156"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "nonInferiorityType": "SUPERIORITY_OR_OTHER_LEGACY", "pValue": "0.7946", "statisticalMethod": "Linear Model", "statisticalComment": "Treatment as a fixed effect and corresponding baseline as a covariate", "paramType": "Mean Difference (Net)", "paramValue": "-0.0812", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.6987", "ciUpperLimit": "0.5362"}]}, {"type": "SECONDARY", "title": "Change From Baseline in Local Aortic Strain at 52 Weeks", "description": "Cardiovascular magnetic resonance imaging (MRI) scans were obtained at baseline prior to randomization, at week 52 for the assessment of local aortic strain. Local aortic strain was measured by assessing ascending aorta strain, proximal descending aorta strain and distal descending aorta strain.", "populationDescription": "Pharmacodynamic (PD) analysis set: All patients with any available PD data, who received any study drug and experienced no protocol deviations with relevant impact on PD data. Patients with both baseline and week 52 data were included in this analysis.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "percent", "timeFrame": "Baseline, 52 weeks", "groups": [{"id": "OG000", "title": "Sacubitril/Valsartan (LCZ696)", "description": "LCZ696 based treatment strategy (LCZ696 200 mg for 2 weeks as initiation dose, LCZ696 400 mg for additional 50 weeks as maintenance dose. Optional amlodipine 2.5 to 10 mg add-on after Week 12 to reach blood pressure target)"}, {"id": "OG001", "title": "Olmesartan", "description": "Olmesartan based treatment strategy (olmesartan 20 mg for 2 weeks as initiation dose, olmesartan 40 mg for additional 50 weeks as maintenance dose. Optional amlodipine 2.5 to 10 mg add-on after Week 12 to reach blood pressure target)"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "49"}, {"groupId": "OG001", "value": "53"}]}], "classes": [{"title": "Ascending Aorta Strain", "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.830", "spread": "0.7903"}, {"groupId": "OG001", "value": "0.453", "spread": "0.7598"}]}]}, {"title": "Proximal Descending Aorta Strain", "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.284", "spread": "0.8940"}, {"groupId": "OG001", "value": "-0.066", "spread": "0.8596"}]}]}, {"title": "Distal Descending Aorta Strain", "categories": [{"measurements": [{"groupId": "OG000", "value": "-1.092", "spread": "1.0956"}, {"groupId": "OG001", "value": "0.225", "spread": "1.0533"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline in Regional Aortic Pulse Wave Velocity at 52 Weeks", "description": "Cardiovascular magnetic resonance imaging (MRI) scans were obtained at baseline prior to randomization, at week 52 for the assessment of regional aortic pulse wave velocity.", "populationDescription": "Pharmacodynamic (PD) analysis set: All patients with any available PD data, who received any study drug and experienced no protocol deviations with relevant impact on PD data. Patients with both baseline and week 52 data were included in this analysis.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "meters per second (m/s)", "timeFrame": "Baseline, 52 weeks", "groups": [{"id": "OG000", "title": "Sacubitril/Valsartan (LCZ696)", "description": "LCZ696 based treatment strategy (LCZ696 200 mg for 2 weeks as initiation dose, LCZ696 400 mg for additional 50 weeks as maintenance dose. Optional amlodipine 2.5 to 10 mg add-on after Week 12 to reach blood pressure target)"}, {"id": "OG001", "title": "Olmesartan", "description": "Olmesartan based treatment strategy (olmesartan 20 mg for 2 weeks as initiation dose, olmesartan 40 mg for additional 50 weeks as maintenance dose. Optional amlodipine 2.5 to 10 mg add-on after Week 12 to reach blood pressure target)"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "49"}, {"groupId": "OG001", "value": "53"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-2.086", "spread": "0.5029"}, {"groupId": "OG001", "value": "-1.085", "spread": "0.4835"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline in Central Blood Pressure at 52 Weeks", "description": "Central blood pressure was determined by measuring central systolic blood pressure , diastolic blood pressure and pulse pressure.", "populationDescription": "Pharmacodynamic (PD) analysis set: All patients with any available PD data, who received any study drug and experienced no protocol deviations with relevant impact on PD data. Patients with both baseline and week 52 data were included in this analysis.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "mmHg", "timeFrame": "Baseline, 52 weeks", "groups": [{"id": "OG000", "title": "Sacubitril/Valsartan (LCZ696)", "description": "LCZ696 based treatment strategy (LCZ696 200 mg for 2 weeks as initiation dose, LCZ696 400 mg for additional 50 weeks as maintenance dose. Optional amlodipine 2.5 to 10 mg add-on after Week 12 to reach blood pressure target)"}, {"id": "OG001", "title": "Olmesartan", "description": "Olmesartan based treatment strategy (olmesartan 20 mg for 2 weeks as initiation dose, olmesartan 40 mg for additional 50 weeks as maintenance dose. Optional amlodipine 2.5 to 10 mg add-on after Week 12 to reach blood pressure target)"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "50"}, {"groupId": "OG001", "value": "50"}]}], "classes": [{"title": "Central systolic blood pressure", "categories": [{"measurements": [{"groupId": "OG000", "value": "-16.655", "spread": "1.4968"}, {"groupId": "OG001", "value": "-13.625", "spread": "1.4968"}]}]}, {"title": "Central diastolic blood pressure", "categories": [{"measurements": [{"groupId": "OG000", "value": "-10.318", "spread": "1.0578"}, {"groupId": "OG001", "value": "-10.432", "spread": "1.0578"}]}]}, {"title": "Central pulse pressure", "categories": [{"measurements": [{"groupId": "OG000", "value": "-6.539", "spread": "0.9428"}, {"groupId": "OG001", "value": "-3.041", "spread": "0.9428"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline in Augmentation Pressure at 52 Weeks", "description": "Augmentation pressure is the added pressure during systole due to wave reflection.", "populationDescription": "Pharmacodynamic (PD) analysis set: All patients with any available PD data, who received any study drug and experienced no protocol deviations with relevant impact on PD data. Patients with both baseline and week 52 data were included in this analysis.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "mmHg", "timeFrame": "Baseline, 52 weeks", "groups": [{"id": "OG000", "title": "Sacubitril/Valsartan (LCZ696)", "description": "LCZ696 based treatment strategy (LCZ696 200 mg for 2 weeks as initiation dose, LCZ696 400 mg for additional 50 weeks as maintenance dose. Optional amlodipine 2.5 to 10 mg add-on after Week 12 to reach blood pressure target)"}, {"id": "OG001", "title": "Olmesartan", "description": "Olmesartan based treatment strategy (olmesartan 20 mg for 2 weeks as initiation dose, olmesartan 40 mg for additional 50 weeks as maintenance dose. Optional amlodipine 2.5 to 10 mg add-on after Week 12 to reach blood pressure target)"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "50"}, {"groupId": "OG001", "value": "50"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-2.443", "spread": "0.5950"}, {"groupId": "OG001", "value": "-1.437", "spread": "0.5950"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline in Augmentation Index at 52 Weeks", "description": "Augmentation index (Alx) is the percentage of the central pulse pressure due to wave reflection.", "populationDescription": "Pharmacodynamic (PD) analysis set: All patients with any available PD data, who received any study drug and experienced no protocol deviations with relevant impact on PD data. Patients with both baseline and week 52 data were included in this analysis", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "percent", "timeFrame": "Baseline, 52 weeks", "groups": [{"id": "OG000", "title": "Sacubitril/Valsartan (LCZ696)", "description": "LCZ696 based treatment strategy (LCZ696 200 mg for 2 weeks as initiation dose, LCZ696 400 mg for additional 50 weeks as maintenance dose. Optional amlodipine 2.5 to 10 mg add-on after Week 12 to reach blood pressure target)"}, {"id": "OG001", "title": "Olmesartan", "description": "Olmesartan based treatment strategy (olmesartan 20 mg for 2 weeks as initiation dose, olmesartan 40 mg for additional 50 weeks as maintenance dose. Optional amlodipine 2.5 to 10 mg add-on after Week 12 to reach blood pressure target)"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "50"}, {"groupId": "OG001", "value": "50"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-2.385", "spread": "1.1805"}, {"groupId": "OG001", "value": "-1.515", "spread": "1.1805"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline in Carotid-femoral Pulse Wave Velocity at 52 Weeks", "description": "For pulse wave velocity calculation, the pressure waveform at the femoral site (using a partially inflated custom blood pressure cuff) and the carotid site (using hand -held applanation tonometry) were measured simultaneously. Pulse wave analysis was performed on the central aortic pressure waveform as derived from the brachial pressure waveform recorded in a partially-inflated blood pressure cuff around the upper arm.", "populationDescription": "Pharmacodynamic (PD) analysis set: All patients with any available PD data, who received any study drug and experienced no protocol deviations with relevant impact on PD data. Patients with both baseline and week 52 data were included in this analysis", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "meters per second (m/s)", "timeFrame": "Baseline, 52 weeks", "groups": [{"id": "OG000", "title": "Sacubitril/Valsartan (LCZ696)", "description": "LCZ696 based treatment strategy (LCZ696 200 mg for 2 weeks as initiation dose, LCZ696 400 mg for additional 50 weeks as maintenance dose. Optional amlodipine 2.5 to 10 mg add-on after Week 12 to reach blood pressure target)"}, {"id": "OG001", "title": "Olmesartan", "description": "Olmesartan based treatment strategy (olmesartan 20 mg for 2 weeks as initiation dose, olmesartan 40 mg for additional 50 weeks as maintenance dose. Optional amlodipine 2.5 to 10 mg add-on after Week 12 to reach blood pressure target)"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "50"}, {"groupId": "OG001", "value": "50"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-0.428", "spread": "0.1663"}, {"groupId": "OG001", "value": "-0.434", "spread": "0.1663"}]}]}]}, {"type": "SECONDARY", "title": "Number of Patients With Reported Adverse Events, Serious Adverse Events and Death", "description": "This outcome measure summarizes patients with any adverse events, serious adverse events and death.", "populationDescription": "Safety analysis set: All patients that received study drug", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "Patients", "timeFrame": "12 weeks", "groups": [{"id": "OG000", "title": "Initiation Dose : Sacubitril/Valsartan (LCZ696 200mg)", "description": "Patients received LCZ696 200 mg for 2 weeks as initiation dose for 2 weeks"}, {"id": "OG001", "title": "Initiation Dose: Olmesartan 20mg", "description": "Patients received olmesartan 20 mg for 2 weeks as initiation dose for 2 weeks"}, {"id": "OG002", "title": "Maintenance Dose: Sacubitril/Valsartan (LCZ696 400mg)", "description": "After 2 weeks on initiation dose, patients were dosed at the maintenance dose level of LCZ696 400 mg for 10 weeks"}, {"id": "OG003", "title": "Maintenance Dose: Olmesartan 40 mg", "description": "After 2 weeks on initiation dose, patients were dosed at the maintenance dose level of olmesartan 40 mg for 10 weeks"}, {"id": "OG004", "title": "Sacubitril/Valsartan (LCZ696 400mg) +/- Amlodipine", "description": "Optional amlodipine 2.5 to 10 mg add-on after Week 12 to reach blood pressure target"}, {"id": "OG005", "title": "Olmesartan 40mg +/- Amlodipine", "description": "Optional amlodipine 2.5 to 10 mg add-on after Week 12 to reach blood pressure target"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "57"}, {"groupId": "OG001", "value": "57"}, {"groupId": "OG002", "value": "57"}, {"groupId": "OG003", "value": "56"}, {"groupId": "OG004", "value": "54"}, {"groupId": "OG005", "value": "53"}]}], "classes": [{"title": "Any Adverse events", "categories": [{"measurements": [{"groupId": "OG000", "value": "13"}, {"groupId": "OG001", "value": "16"}, {"groupId": "OG002", "value": "21"}, {"groupId": "OG003", "value": "28"}, {"groupId": "OG004", "value": "31"}, {"groupId": "OG005", "value": "38"}]}]}, {"title": "Serious Adverse Events", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "2"}, {"groupId": "OG002", "value": "0"}, {"groupId": "OG003", "value": "2"}, {"groupId": "OG004", "value": "6"}, {"groupId": "OG005", "value": "5"}]}]}, {"title": "Death", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}, {"groupId": "OG002", "value": "0"}, {"groupId": "OG003", "value": "0"}, {"groupId": "OG004", "value": "0"}, {"groupId": "OG005", "value": "0"}]}]}]}]}, "adverseEventsModule": {"frequencyThreshold": "5", "eventGroups": [{"id": "EG000", "title": "Initiation Dose : Sacubitril/Valsartan (LCZ696 200mg)", "description": "Patients received LCZ696 200 mg for 2 weeks as initiation dose for 2 weeks", "seriousNumAffected": 0, "seriousNumAtRisk": 57, "otherNumAffected": 3, "otherNumAtRisk": 57}, {"id": "EG001", "title": "Initiation Dose: Olmesartan 20mg", "description": "Patients received olmesartan 20 mg for 2 weeks as initiation dose for 2 weeks", "seriousNumAffected": 2, "seriousNumAtRisk": 57, "otherNumAffected": 6, "otherNumAtRisk": 57}, {"id": "EG002", "title": "Maintenance Dose: Sacubitril/Valsartan (LCZ696 400mg)", "description": "After 2 weeks on initiation dose, patients were dosed at the maintenance dose level of LCZ696 400 mg for 10 weeks", "seriousNumAffected": 0, "seriousNumAtRisk": 57, "otherNumAffected": 10, "otherNumAtRisk": 57}, {"id": "EG003", "title": "Maintenance Dose: Olmesartan 40 mg", "description": "After 2 weeks on initiation dose, patients were dosed at the maintenance dose level of olmesartan 40 mg for 10 weeks", "seriousNumAffected": 2, "seriousNumAtRisk": 56, "otherNumAffected": 14, "otherNumAtRisk": 56}, {"id": "EG004", "title": "Sacubitril/Valsartan (LCZ696 400mg) +/- Amlodipine", "description": "Optional amlodipine 2.5 to 10 mg add-on after Week 12 to reach blood pressure target", "seriousNumAffected": 6, "seriousNumAtRisk": 54, "otherNumAffected": 16, "otherNumAtRisk": 54}, {"id": "EG005", "title": "Olmesartan 40mg +/- Amlodipine", "description": "Optional amlodipine 2.5 to 10 mg add-on after Week 12 to reach blood pressure target", "seriousNumAffected": 5, "seriousNumAtRisk": 53, "otherNumAffected": 24, "otherNumAtRisk": 53}], "seriousEvents": [{"term": "Enterocolitis", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 57}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 57}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 57}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 56}, {"groupId": "EG004", "numAffected": 1, "numAtRisk": 54}, {"groupId": "EG005", "numAffected": 0, "numAtRisk": 53}]}, {"term": "Inguinal hernia", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 57}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 57}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 57}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 56}, {"groupId": "EG004", "numAffected": 1, "numAtRisk": 54}, {"groupId": "EG005", "numAffected": 0, "numAtRisk": 53}]}, {"term": "Fat necrosis", "organSystem": "General disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 57}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 57}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 57}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 56}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 54}, {"groupId": "EG005", "numAffected": 0, "numAtRisk": 53}]}, {"term": "Nodule", "organSystem": "General disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 57}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 57}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 57}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 56}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 54}, {"groupId": "EG005", "numAffected": 0, "numAtRisk": 53}]}, {"term": "Appendicitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 57}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 57}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 57}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 56}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 54}, {"groupId": "EG005", "numAffected": 0, "numAtRisk": 53}]}, {"term": "Gastroenteritis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 57}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 57}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 57}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 56}, {"groupId": "EG004", "numAffected": 1, "numAtRisk": 54}, {"groupId": "EG005", "numAffected": 1, "numAtRisk": 53}]}, {"term": "Abdominal injury", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 57}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 57}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 57}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 56}, {"groupId": "EG004", "numAffected": 1, "numAtRisk": 54}, {"groupId": "EG005", "numAffected": 0, "numAtRisk": 53}]}, {"term": "Fall", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 57}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 57}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 57}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 56}, {"groupId": "EG004", "numAffected": 1, "numAtRisk": 54}, {"groupId": "EG005", "numAffected": 0, "numAtRisk": 53}]}, {"term": "Road traffic accident", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 57}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 57}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 57}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 56}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 54}, {"groupId": "EG005", "numAffected": 1, "numAtRisk": 53}]}, {"term": "Tendon rupture", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 57}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 57}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 57}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 56}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 54}, {"groupId": "EG005", "numAffected": 2, "numAtRisk": 53}]}, {"term": "Dehydration", "organSystem": "Metabolism and nutrition disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 57}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 57}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 57}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 56}, {"groupId": "EG004", "numAffected": 1, "numAtRisk": 54}, {"groupId": "EG005", "numAffected": 0, "numAtRisk": 53}]}, {"term": "Adenocarcinoma of colon", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 57}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 57}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 57}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 56}, {"groupId": "EG004", "numAffected": 1, "numAtRisk": 54}, {"groupId": "EG005", "numAffected": 0, "numAtRisk": 53}]}, {"term": "Intraductal proliferative breast lesion", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 57}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 57}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 57}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 56}, {"groupId": "EG004", "numAffected": 1, "numAtRisk": 54}, {"groupId": "EG005", "numAffected": 0, "numAtRisk": 53}]}, {"term": "Metastases to bone", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 57}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 57}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 57}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 56}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 54}, {"groupId": "EG005", "numAffected": 0, "numAtRisk": 53}]}, {"term": "Prostate cancer metastatic", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 57}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 57}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 57}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 56}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 54}, {"groupId": "EG005", "numAffected": 0, "numAtRisk": 53}]}, {"term": "Syncope", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 57}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 57}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 57}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 56}, {"groupId": "EG004", "numAffected": 1, "numAtRisk": 54}, {"groupId": "EG005", "numAffected": 0, "numAtRisk": 53}]}, {"term": "Acute kidney injury", "organSystem": "Renal and urinary disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 57}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 57}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 57}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 56}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 54}, {"groupId": "EG005", "numAffected": 1, "numAtRisk": 53}]}, {"term": "Haematuria", "organSystem": "Renal and urinary disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 57}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 57}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 57}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 56}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 54}, {"groupId": "EG005", "numAffected": 1, "numAtRisk": 53}]}, {"term": "Hypertension", "organSystem": "Vascular disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 57}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 57}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 57}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 56}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 54}, {"groupId": "EG005", "numAffected": 0, "numAtRisk": 53}]}, {"term": "Hypertensive crisis", "organSystem": "Vascular disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 57}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 57}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 57}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 56}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 54}, {"groupId": "EG005", "numAffected": 1, "numAtRisk": 53}]}], "otherEvents": [{"term": "Oedema peripheral", "organSystem": "General disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 57}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 57}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 57}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 56}, {"groupId": "EG004", "numAffected": 1, "numAtRisk": 54}, {"groupId": "EG005", "numAffected": 4, "numAtRisk": 53}]}, {"term": "Influenza", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 57}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 57}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 57}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 56}, {"groupId": "EG004", "numAffected": 1, "numAtRisk": 54}, {"groupId": "EG005", "numAffected": 3, "numAtRisk": 53}]}, {"term": "Nasopharyngitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 57}, {"groupId": "EG001", "numAffected": 2, "numAtRisk": 57}, {"groupId": "EG002", "numAffected": 4, "numAtRisk": 57}, {"groupId": "EG003", "numAffected": 5, "numAtRisk": 56}, {"groupId": "EG004", "numAffected": 11, "numAtRisk": 54}, {"groupId": "EG005", "numAffected": 10, "numAtRisk": 53}]}, {"term": "Blood creatine phosphokinase increased", "organSystem": "Investigations", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 57}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 57}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 57}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 56}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 54}, {"groupId": "EG005", "numAffected": 3, "numAtRisk": 53}]}, {"term": "Arthralgia", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 57}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 57}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 57}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 56}, {"groupId": "EG004", "numAffected": 1, "numAtRisk": 54}, {"groupId": "EG005", "numAffected": 3, "numAtRisk": 53}]}, {"term": "Back pain", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 57}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 57}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 57}, {"groupId": "EG003", "numAffected": 5, "numAtRisk": 56}, {"groupId": "EG004", "numAffected": 1, "numAtRisk": 54}, {"groupId": "EG005", "numAffected": 5, "numAtRisk": 53}]}, {"term": "Dizziness", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 57}, {"groupId": "EG001", "numAffected": 2, "numAtRisk": 57}, {"groupId": "EG002", "numAffected": 4, "numAtRisk": 57}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 56}, {"groupId": "EG004", "numAffected": 1, "numAtRisk": 54}, {"groupId": "EG005", "numAffected": 0, "numAtRisk": 53}]}, {"term": "Headache", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 57}, {"groupId": "EG001", "numAffected": 2, "numAtRisk": 57}, {"groupId": "EG002", "numAffected": 2, "numAtRisk": 57}, {"groupId": "EG003", "numAffected": 6, "numAtRisk": 56}, {"groupId": "EG004", "numAffected": 2, "numAtRisk": 54}, {"groupId": "EG005", "numAffected": 2, "numAtRisk": 53}]}, {"term": "Haematuria", "organSystem": "Renal and urinary disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 57}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 57}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 57}, {"groupId": "EG003", "numAffected": 2, "numAtRisk": 56}, {"groupId": "EG004", "numAffected": 3, "numAtRisk": 54}, {"groupId": "EG005", "numAffected": 0, "numAtRisk": 53}]}]}, "moreInfoModule": {"certainAgreement": {"piSponsorEmployee": false, "restrictionType": "OTHER", "restrictiveAgreement": true, "otherDetails": "The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial or disclosure of trial results in their entirety."}, "pointOfContact": {"title": "Study Director", "organization": "Novartis Pharmaceuticals", "email": "trialandresults.registries@novartis.com", "phone": "862-778-8300"}}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-07-01"}, "conditionBrowseModule": {"meshes": [{"id": "D000006973", "term": "Hypertension"}], "ancestors": [{"id": "D000014652", "term": "Vascular Diseases"}, {"id": "D000002318", "term": "Cardiovascular Diseases"}], "browseLeaves": [{"id": "M10024", "name": "Hypertension", "asFound": "Hypertension", "relevance": "HIGH"}, {"id": "M1470", "name": "Essential Hypertension", "relevance": "LOW"}, {"id": "M17400", "name": "Vascular Diseases", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC14", "name": "Heart and Blood Diseases"}, {"abbrev": "All", "name": "All Conditions"}]}, "interventionBrowseModule": {"meshes": [{"id": "D000017311", "term": "Amlodipine"}, {"id": "D000068756", "term": "Valsartan"}, {"id": "C000437965", "term": "Olmesartan"}, {"id": "D000068557", "term": "Olmesartan Medoxomil"}, {"id": "C000549068", "term": "Sacubitril and valsartan sodium hydrate drug combination"}], "ancestors": [{"id": "D000000959", "term": "Antihypertensive Agents"}, {"id": "D000002121", "term": "Calcium Channel Blockers"}, {"id": "D000049990", "term": "Membrane Transport Modulators"}, {"id": "D000045504", "term": "Molecular Mechanisms of Pharmacological Action"}, {"id": "D000077264", "term": "Calcium-Regulating Hormones and Agents"}, {"id": "D000045505", "term": "Physiological Effects of Drugs"}, {"id": "D000014665", "term": "Vasodilator Agents"}, {"id": "D000047228", "term": "Angiotensin II Type 1 Receptor Blockers"}, {"id": "D000057911", "term": "Angiotensin Receptor Antagonists"}], "browseLeaves": [{"id": "M19600", "name": "Amlodipine", "asFound": "Healthy Volunteers", "relevance": "HIGH"}, {"id": "M301", "name": "Valsartan", "asFound": "Extended", "relevance": "HIGH"}, {"id": "M350410", "name": "Sacubitril and valsartan sodium hydrate drug combination", "asFound": "Pea", "relevance": "HIGH"}, {"id": "M91890", "name": "Olmesartan", "asFound": "Anticoagulation", "relevance": "HIGH"}, {"id": "M273", "name": "Olmesartan Medoxomil", "asFound": "Anticoagulation", "relevance": "HIGH"}, {"id": "M4277", "name": "Antihypertensive Agents", "relevance": "LOW"}, {"id": "M5381", "name": "Calcium", "relevance": "LOW"}, {"id": "M5398", "name": "Calcium, Dietary", "relevance": "LOW"}, {"id": "M5384", "name": "Calcium Channel Blockers", "relevance": "LOW"}, {"id": "M9789", "name": "Hormones", "relevance": "LOW"}, {"id": "M17412", "name": "Vasodilator Agents", "relevance": "LOW"}, {"id": "M4132", "name": "Angiotensin II", "relevance": "LOW"}, {"id": "M289354", "name": "Giapreza", "relevance": "LOW"}, {"id": "M4135", "name": "Angiotensinogen", "relevance": "LOW"}, {"id": "M25789", "name": "Angiotensin II Type 1 Receptor Blockers", "relevance": "LOW"}, {"id": "M28916", "name": "Angiotensin Receptor Antagonists", "relevance": "LOW"}], "browseBranches": [{"abbrev": "AnAg", "name": "Antihypertensive Agents"}, {"abbrev": "ChanBlk", "name": "Channel Blockers"}, {"abbrev": "VaDiAg", "name": "Vasodilator Agents"}, {"abbrev": "All", "name": "All Drugs and Chemicals"}, {"abbrev": "BDCA", "name": "Bone Density Conservation Agents"}, {"abbrev": "VaCoAg", "name": "Vasoconstrictor Agents"}]}}, "hasResults": true}